Press Releases

04.16.2015

Pfizer Launches 2014 Integrated Annual Review

04.15.2015

Pfizer Announces PALOMA-3 Trial For IBRANCE® (Palbociclib) Stopped Early Due To Efficacy Seen In Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy

04.14.2015

REGiMMUNE Announces Collaboration with JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells

04.09.2015

Pfizer Launches First Annual PCSK9 Competitive Grants Program to Advance Cardiovascular Disease Research

04.07.2015

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI® (crizotinib)

04.06.2015

Kathrin U. Jansen, Ph.D., to Lead Pfizer’s Vaccine Research and Development Unit

03.30.2015

Dr. Charles Reay Mackay To Join Pfizer as Chief Scientific Officer, Inflammation and Immunology Research Unit

03.26.2015

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.23.2015

Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

03.20.2015

Pfizer Announces Oral Tofacitinib Meets Primary Endpoints In Pivotal Phase 3 Psoriasis Trials

03.18.2015

Results of Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Published in the New England Journal of Medicine

03.12.2015

Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia